High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis.

ABSTRACT: Tuberculous meningitis (TB meningitis) is the most severe form of tuberculosis (TB), requiring 12 months of multidrug treatment for cure, and is associated with high morbidity and mortality. High-dose rifampin (35 mg/kg/d) is safe and improves the bactericidal activity of the standard-dose (10 mg/kg/d) rifampin-containing TB regimen in pulmonary TB. However, there are conflicting clinical data regarding its benefit for TB meningitis, where outcomes may also be associated with intracerebral inflammation. We conducted cross-species studies in mice and rabbits, demonstrating that an intensified high-dose rifampin-containing regimen has significantly improved bactericidal activity for TB meningitis over the first-line, standard-dose rifampin regimen, without an increase in intracerebral inflam

SUBMITTER: Ruiz-Bedoya CA 

PROVIDER: S-EPMC8920328 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature